FBIO and DERM Related Headlines
Go Back- Journey Medical publishes Emrosi clinical trial results in dermatology journal
- Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
- Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
- Journey Medical presents Emrosi clinical trial data at dermatology conference
- Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
- Journey Medical Corporation to Participate in October 2025 Investor Conferences
- Journey Medical Corporation to Participate in September 2025 Investor Conferences
- Journey Medical Corporation to Present at the Emerging Growth Conference
- Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
- Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
- Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
- Journey Medical expands Emrosi payer coverage to 65% of commercial lives
- Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
- Journey Medical Corp (DERM) set to join Russell 2000 and 3000
- Journey Medical to Join Russell 2000® and Russell 3000® Indexes
- Journey Medical Corp (DERM) Announces Emrosi Data Analysis to be Presented at SDPA
- Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
- Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
FBIO and DERM Related Press Releases
Go Back- Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
- Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
- Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
- Journey Medical Corporation to Participate in October 2025 Investor Conferences
- Journey Medical Corporation to Participate in September 2025 Investor Conferences
- Journey Medical Corporation to Present at the Emerging Growth Conference
- Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
- Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
- Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
- Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
- Journey Medical to Join Russell 2000® and Russell 3000® Indexes
- Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
- Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
